Bio-Techne Corporation (TECH)
USD 50.06
(-3.21%)
USD 50.06
(-3.21%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | 206.68 Million USD | -30.86% |
| 2023 | 298.94 Million USD | 0.79% |
| 2022 | 296.59 Million USD | 98.32% |
| 2021 | 149.54 Million USD | 100.25% |
| 2020 | 74.68 Million USD | -40.53% |
| 2019 | 125.58 Million USD | -7.78% |
| 2018 | 136.17 Million USD | 11.82% |
| 2017 | 121.78 Million USD | -19.13% |
| 2016 | 150.59 Million USD | 2.43% |
| 2015 | 147.02 Million USD | -7.97% |
| 2014 | 159.75 Million USD | 0.81% |
| 2013 | 158.46 Million USD | -4.66% |
| 2012 | 166.2 Million USD | 1.93% |
| 2011 | 163.05 Million USD | 4.3% |
| 2010 | 156.32 Million USD | 3.68% |
| 2009 | 150.78 Million USD | 4.5% |
| 2008 | 144.28 Million USD | 16.22% |
| 2007 | 124.15 Million USD | 14.42% |
| 2006 | 108.5 Million USD | 10.99% |
| 2005 | 97.76 Million USD | 18.83% |
| 2004 | 82.27 Million USD | 21.49% |
| 2003 | 67.71 Million USD | 28.21% |
| 2002 | 52.81 Million USD | 15.31% |
| 2001 | 45.8 Million USD | 16.42% |
| 2000 | 39.34 Million USD | 56.75% |
| 1999 | 25.1 Million USD | 18.4% |
| 1998 | 21.2 Million USD | 38.56% |
| 1997 | 15.3 Million USD | 25.41% |
| 1996 | 12.2 Million USD | 29.79% |
| 1995 | 9.4 Million USD | 23.68% |
| 1994 | 7.6 Million USD | 10.14% |
| 1993 | 6.9 Million USD | 68.29% |
| 1992 | 4.1 Million USD | 86.36% |
| 1991 | 2.2 Million USD | 46.67% |
| 1990 | 1.5 Million USD | 150.0% |
| 1989 | 600 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 38 Million USD | -31.97% |
| 2024 Q1 | 55.86 Million USD | -40.9% |
| 2024 Q3 | 71.98 Million USD | 89.4% |
| 2024 Q4 | 78.99 Million USD | 9.74% |
| 2024 FY | 253.04 Million USD | -15.35% |
| 2023 FY | 298.94 Million USD | 0.79% |
| 2023 Q1 | 56.31 Million USD | -30.1% |
| 2023 Q2 | 67.89 Million USD | 20.55% |
| 2023 Q4 | 94.52 Million USD | 17.85% |
| 2023 Q3 | 80.21 Million USD | 18.15% |
| 2022 Q3 | 90.44 Million USD | 45.07% |
| 2022 Q4 | 80.57 Million USD | -10.92% |
| 2022 FY | 296.59 Million USD | 98.32% |
| 2022 Q2 | 62.34 Million USD | -1.38% |
| 2022 Q1 | 63.22 Million USD | -7.82% |
| 2021 Q3 | 68.62 Million USD | 34.57% |
| 2021 Q4 | 68.58 Million USD | -0.06% |
| 2021 Q1 | 49.09 Million USD | 24.88% |
| 2021 Q2 | 50.99 Million USD | 3.88% |
| 2021 FY | 149.54 Million USD | 100.25% |
| 2020 Q4 | 39.31 Million USD | -17.74% |
| 2020 Q1 | 33.32 Million USD | -22.97% |
| 2020 Q2 | 36.99 Million USD | 11.0% |
| 2020 Q3 | 47.79 Million USD | 29.19% |
| 2020 FY | 74.68 Million USD | -40.53% |
| 2019 FY | 125.58 Million USD | -7.78% |
| 2019 Q1 | 25.76 Million USD | -39.97% |
| 2019 Q4 | 43.26 Million USD | -1.88% |
| 2019 Q3 | 44.09 Million USD | 31.21% |
| 2019 Q2 | 33.6 Million USD | 30.43% |
| 2018 Q1 | 26.03 Million USD | -37.24% |
| 2018 FY | 136.17 Million USD | 11.82% |
| 2018 Q4 | 42.91 Million USD | -0.39% |
| 2018 Q3 | 43.08 Million USD | 78.42% |
| 2018 Q2 | 24.14 Million USD | -7.23% |
| 2017 Q2 | 16.14 Million USD | -36.54% |
| 2017 Q3 | 32.3 Million USD | 100.08% |
| 2017 Q1 | 25.44 Million USD | -36.41% |
| 2017 FY | 121.78 Million USD | -19.13% |
| 2017 Q4 | 41.47 Million USD | 28.39% |
| 2016 Q1 | 31.02 Million USD | -17.92% |
| 2016 FY | 150.59 Million USD | 2.43% |
| 2016 Q2 | 36.02 Million USD | 16.1% |
| 2016 Q4 | 40.01 Million USD | -8.08% |
| 2016 Q3 | 43.52 Million USD | 20.82% |
| 2015 Q3 | 39.42 Million USD | 14.01% |
| 2015 FY | 147.02 Million USD | -7.97% |
| 2015 Q4 | 37.8 Million USD | -4.12% |
| 2015 Q2 | 34.58 Million USD | -1.81% |
| 2015 Q1 | 35.21 Million USD | -9.34% |
| 2014 Q1 | 39.39 Million USD | -1.07% |
| 2014 Q2 | 35.74 Million USD | -9.26% |
| 2014 FY | 159.75 Million USD | 0.81% |
| 2014 Q4 | 38.84 Million USD | -15.13% |
| 2014 Q3 | 45.76 Million USD | 28.05% |
| 2013 FY | 158.46 Million USD | -4.66% |
| 2013 Q4 | 39.81 Million USD | -9.4% |
| 2013 Q3 | 43.94 Million USD | 19.08% |
| 2013 Q2 | 36.9 Million USD | -2.38% |
| 2013 Q1 | 37.8 Million USD | -8.29% |
| 2012 Q1 | 40.94 Million USD | -3.89% |
| 2012 Q3 | 46.36 Million USD | 23.03% |
| 2012 Q2 | 37.68 Million USD | -7.97% |
| 2012 Q4 | 41.21 Million USD | -11.1% |
| 2012 FY | 166.2 Million USD | 1.93% |
| 2011 Q4 | 42.6 Million USD | -4.77% |
| 2011 FY | 163.05 Million USD | 4.3% |
| 2011 Q1 | 38.36 Million USD | -1.44% |
| 2011 Q2 | 37.35 Million USD | -2.64% |
| 2011 Q3 | 44.73 Million USD | 19.78% |
| 2010 Q1 | 39.2 Million USD | 7.59% |
| 2010 FY | 156.32 Million USD | 3.68% |
| 2010 Q4 | 38.92 Million USD | -6.54% |
| 2010 Q3 | 41.64 Million USD | 13.94% |
| 2010 Q2 | 36.55 Million USD | -6.75% |
| 2009 Q2 | 32.65 Million USD | -20.83% |
| 2009 Q3 | 40.44 Million USD | 23.83% |
| 2009 Q4 | 36.43 Million USD | -9.9% |
| 2009 FY | 150.78 Million USD | 4.5% |
| 2009 Q1 | 41.24 Million USD | 6.31% |
| 2008 FY | 144.28 Million USD | 16.22% |
| 2008 Q3 | 40.26 Million USD | 22.36% |
| 2008 Q1 | 32.32 Million USD | -0.45% |
| 2008 Q2 | 32.9 Million USD | 1.79% |
| 2008 Q4 | 38.8 Million USD | -3.62% |
| 2007 Q4 | 32.47 Million USD | -8.21% |
| 2007 FY | 124.15 Million USD | 14.42% |
| 2007 Q3 | 35.37 Million USD | 28.56% |
| 2007 Q2 | 27.51 Million USD | -4.42% |
| 2007 Q1 | 28.78 Million USD | 0.27% |
| 2006 Q2 | 24.28 Million USD | -2.65% |
| 2006 Q1 | 24.95 Million USD | -6.85% |
| 2006 FY | 108.5 Million USD | 10.99% |
| 2006 Q4 | 28.71 Million USD | -6.03% |
| 2006 Q3 | 30.55 Million USD | 25.8% |
| 2005 Q1 | 21.4 Million USD | -3.91% |
| 2005 FY | 97.76 Million USD | 18.83% |
| 2005 Q2 | 22.09 Million USD | 3.2% |
| 2005 Q4 | 26.78 Million USD | -2.54% |
| 2005 Q3 | 27.48 Million USD | 24.4% |
| 2004 Q1 | 18.88 Million USD | -0.92% |
| 2004 Q3 | 22.65 Million USD | 22.77% |
| 2004 Q4 | 22.27 Million USD | -1.68% |
| 2004 Q2 | 18.45 Million USD | -2.27% |
| 2004 FY | 82.27 Million USD | 21.49% |
| 2003 Q4 | 19.05 Million USD | 3.0% |
| 2003 Q3 | 18.5 Million USD | 27.05% |
| 2003 FY | 67.71 Million USD | 28.21% |
| 2003 Q1 | 15.43 Million USD | 5.95% |
| 2003 Q2 | 14.56 Million USD | -5.67% |
| 2002 FY | 52.81 Million USD | 15.31% |
| 2002 Q1 | 11.63 Million USD | -47.65% |
| 2002 Q2 | 11.82 Million USD | 1.69% |
| 2002 Q3 | 14.78 Million USD | 25.02% |
| 2002 Q4 | 14.57 Million USD | -1.46% |
| 2001 FY | 45.8 Million USD | 16.42% |
| 2001 Q4 | 22.22 Million USD | 148.08% |
| 2001 Q3 | 8.95 Million USD | -9.98% |
| 2001 Q2 | 9.95 Million USD | -9.15% |
| 2001 Q1 | 10.95 Million USD | -8.01% |
| 2000 Q3 | 11.26 Million USD | 34.07% |
| 2000 Q1 | 7.7 Million USD | 1.32% |
| 2000 Q2 | 8.4 Million USD | 9.09% |
| 2000 FY | 39.34 Million USD | 56.75% |
| 2000 Q4 | 11.9 Million USD | 5.71% |
| 1999 Q4 | 7.6 Million USD | 10.14% |
| 1999 Q3 | 6.9 Million USD | 25.45% |
| 1999 FY | 25.1 Million USD | 18.4% |
| 1999 Q2 | 5.5 Million USD | 7.84% |
| 1999 Q1 | 5.1 Million USD | -25.0% |
| 1998 Q4 | 6.8 Million USD | 17.24% |
| 1998 Q3 | 5.8 Million USD | 38.1% |
| 1998 Q2 | 4.2 Million USD | -6.67% |
| 1998 Q1 | 4.5 Million USD | -10.0% |
| 1998 FY | 21.2 Million USD | 38.56% |
| 1997 Q1 | 3 Million USD | -21.05% |
| 1997 FY | 15.3 Million USD | 25.41% |
| 1997 Q2 | 3.2 Million USD | 6.67% |
| 1997 Q3 | 4.2 Million USD | 31.25% |
| 1997 Q4 | 5 Million USD | 19.05% |
| 1996 FY | 12.2 Million USD | 29.79% |
| 1996 Q4 | 3.8 Million USD | 5.56% |
| 1996 Q3 | 3.6 Million USD | 63.64% |
| 1996 Q1 | 2.5 Million USD | -10.71% |
| 1996 Q2 | 2.2 Million USD | -12.0% |
| 1995 Q1 | 2.1 Million USD | -16.0% |
| 1995 Q2 | 2 Million USD | -4.76% |
| 1995 Q3 | 2.6 Million USD | 30.0% |
| 1995 Q4 | 2.8 Million USD | 7.69% |
| 1995 FY | 9.4 Million USD | 23.68% |
| 1994 Q1 | 1.6 Million USD | -11.11% |
| 1994 FY | 7.6 Million USD | 10.14% |
| 1994 Q3 | 2.1 Million USD | 61.54% |
| 1994 Q4 | 2.5 Million USD | 19.05% |
| 1994 Q2 | 1.3 Million USD | -18.75% |
| 1993 FY | 6.9 Million USD | 68.29% |
| 1993 Q1 | 1.5 Million USD | -28.57% |
| 1993 Q2 | 1.5 Million USD | 0.0% |
| 1993 Q3 | 2 Million USD | 33.33% |
| 1993 Q4 | 1.8 Million USD | -10.0% |
| 1992 Q4 | 2.1 Million USD | 75.0% |
| 1992 Q3 | 1.2 Million USD | 71.43% |
| 1992 Q2 | 700 Thousand USD | 133.33% |
| 1992 FY | 4.1 Million USD | 86.36% |
| 1992 Q1 | 300 Thousand USD | -62.5% |
| 1991 Q2 | 400 Thousand USD | 0.0% |
| 1991 Q4 | 800 Thousand USD | 14.29% |
| 1991 Q1 | 400 Thousand USD | -42.86% |
| 1991 Q3 | 700 Thousand USD | 75.0% |
| 1991 FY | 2.2 Million USD | 46.67% |
| 1990 FY | 1.5 Million USD | 150.0% |
| 1990 Q4 | 700 Thousand USD | 75.0% |
| 1990 Q2 | 200 Thousand USD | 0.0% |
| 1990 Q3 | 400 Thousand USD | 100.0% |
| 1990 Q1 | 200 Thousand USD | 0.0% |
| 1989 FY | 600 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -237.2 Million USD | 187.133% |
| Alkermes plc | 414.12 Million USD | 50.091% |
| Agenus Inc. | -159.54 Million USD | 229.544% |
| Aptorum Group Limited | -10.52 Million USD | 2064.074% |
| Ardelyx, Inc. | -63.27 Million USD | 426.642% |
| Dyadic International, Inc. | -8.22 Million USD | 2611.453% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | 17439.43% |
| Lantern Pharma Inc. | -17.87 Million USD | 1256.119% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 1128.811% |
| Novavax, Inc. | -566.51 Million USD | 136.484% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 383.213% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 351.455% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 1164.376% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 2056.698% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 489.046% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 154.32% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 950.328% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 645.792% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 260.237% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 346.307% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 1278.437% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 569.634% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 931.935% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 248.662% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 173.247% |
| AlloVir, Inc. | -181.33 Million USD | 213.983% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 200.821% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 806.426% |
| Bicycle Therapeutics plc | -189.94 Million USD | 208.813% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 220.319% |
| ChromaDex Corporation | -5.59 Million USD | 3791.481% |
| Chimerix, Inc. | -93.06 Million USD | 322.088% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 558.515% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 278.087% |
| CRISPR Therapeutics AG | -222.53 Million USD | 192.877% |
| Precision BioSciences, Inc. | -43.73 Million USD | 572.576% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 208.49% |
| Fortress Biotech, Inc. | -142.34 Million USD | 245.204% |
| Fortress Biotech, Inc. | -142.34 Million USD | 245.204% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 311.565% |
| ImmuCell Corporation | -5.74 Million USD | 3695.741% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 253.751% |
| Immix Biopharma, Inc. | -16.14 Million USD | 1380.494% |
| Incyte Corporation | 620.52 Million USD | 66.692% |
| Innoviva, Inc. | 176.7 Million USD | -16.964% |
| IO Biotech, Inc. | -91.44 Million USD | 326.027% |
| Jaguar Health, Inc. | -34.29 Million USD | 702.741% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 221.622% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | -1630.749% |
| ContextLogic Inc. | -328 Million USD | 163.014% |
| MiMedx Group, Inc. | 37.11 Million USD | -456.865% |
| MEI Pharma, Inc. | 14.54 Million USD | -1321.304% |
| NextCure, Inc. | -67.63 Million USD | 405.581% |
| Onconetix, Inc. | -36.03 Million USD | 673.577% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 595.484% |
| Opthea Limited | -191.84 Million USD | 207.737% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 7610.87% |
| Vaxcyte, Inc. | -468.04 Million USD | 144.16% |
| PDS Biotechnology Corporation | -43.04 Million USD | 580.16% |
| Precigen, Inc. | -88.92 Million USD | 332.433% |
| Pharming Group N.V. | -4.87 Million USD | 4335.765% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 223.533% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 794.603% |
| PureTech Health plc | -146.19 Million USD | 241.373% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 1108.667% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 187.728% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 950.328% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 175.431% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 805.293% |
| Acelyrin, Inc. | -422.06 Million USD | 148.97% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | 1602945.767% |
| Summit Therapeutics Inc. | -89.73 Million USD | 330.327% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 657.646% |
| Senti Biosciences, Inc. | -92.72 Million USD | 322.897% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 280.082% |
| Elevation Oncology, Inc. | -45.44 Million USD | 554.805% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 703.163% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 5343.112% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | 6636.559% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 725.923% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 2531.314% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 403.968% |
| Seer, Inc. | -103.46 Million USD | 299.768% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 414.308% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 387.331% |
| ESSA Pharma Inc. | -32.13 Million USD | 743.198% |
| GlycoMimetics, Inc. | -39.27 Million USD | 626.249% |
| GT Biopharma, Inc. | -13.57 Million USD | 1622.437% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 194.282% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 546.831% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -138.085% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 464.147% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 501.285% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 2179.829% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 140.984% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 3096.318% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 507.721% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 179.599% |
| Aptose Biosciences Inc. | -52.35 Million USD | 494.77% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 1533.252% |
| Soligenix, Inc. | -7.69 Million USD | 2784.952% |
| Century Therapeutics, Inc. | -146.54 Million USD | 241.038% |
| Kura Oncology, Inc. | -165.8 Million USD | 224.657% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 321.154% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 2584.505% |
| Ocean Biomedical, Inc. | -2.48 Million USD | 8428.609% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | 3287.631% |
| Autolus Therapeutics plc | -195.02 Million USD | 205.978% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 344.145% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 380.587% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 1077.932% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 191.037% |
| GRI Bio, Inc. | -11.38 Million USD | 1915.105% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 4677.038% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 257.543% |
| IGM Biosciences, Inc. | -263.46 Million USD | 178.45% |
| INmune Bio, Inc. | -29.74 Million USD | 794.953% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 286.852% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 642.835% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 1393.456% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 1410.559% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 438.286% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 292.227% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 174.885% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 201.716% |
| Verastem, Inc. | -92.08 Million USD | 324.454% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 538.498% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 212.241% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 274.595% |
| Histogen Inc. | -10.64 Million USD | 2041.99% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 1435.875% |
| Surrozen, Inc. | -45.78 Million USD | 551.477% |
| Organovo Holdings, Inc. | -15.08 Million USD | 1470.052% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 4160.44% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 448.652% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 502.944% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 917.587% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | 2807.851% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 220.669% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 526.615% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 364.287% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 1457.92% |
| Apollomics, Inc. | -54.83 Million USD | 476.93% |
| Amarin Corporation plc | -67.58 Million USD | 405.803% |
| Mesoblast Limited | -58.79 Million USD | 451.543% |
| Turnstone Biologics Corp. | -59.03 Million USD | 450.125% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 224.863% |
| Synaptogenix, Inc. | -8.31 Million USD | 2586.043% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 1517.016% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 325.416% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 4413.628% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 2440.397% |
| Exelixis, Inc. | 170.88 Million USD | -20.95% |
| Better Therapeutics, Inc. | -38.26 Million USD | 640.186% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 233.292% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 139.969% |
| NLS Pharmaceutics AG | -11.8 Million USD | 1850.528% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | 2670.112% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 789.114% |
| Gritstone bio, Inc. | -154.63 Million USD | 233.661% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 400.15% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 1307.063% |
| Avid Bioservices, Inc. | -18.67 Million USD | 1206.575% |
| Insmed Incorporated | -709.62 Million USD | 129.126% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 1417.328% |
| MediWound Ltd. | -15.29 Million USD | 1451.772% |
| OmniAb, Inc. | -69.41 Million USD | 397.737% |
| Alector, Inc. | -151.74 Million USD | 236.211% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 291.406% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 496.345% |
| Zai Lab Limited | -366.57 Million USD | 156.383% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 165.247% |
| Aura Biosciences, Inc. | -84.99 Million USD | 343.186% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 184.19% |
| Immunic, Inc. | -99.22 Million USD | 308.305% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 244.376% |
| Veracyte, Inc. | -85.79 Million USD | 340.907% |
| InMed Pharmaceuticals Inc. | - USD | -Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 173.341% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 1554.511% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | 3100.691% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 1199.826% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 64.277% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 912.03% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | -432.668% |
| TG Therapeutics, Inc. | 20.63 Million USD | -901.725% |
| Galecto, Inc. | -39.9 Million USD | 617.945% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 591.244% |
| Fortrea Holdings Inc. | 63.1 Million USD | -227.553% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 247.165% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 815.721% |
| XBiotech Inc. | -37.51 Million USD | 651.016% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 400.15% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 407.935% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 291.543% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 905.103% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 487.837% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 136.311% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 363.321% |
| Vaxxinity, Inc. | -58.28 Million USD | 454.613% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 299.294% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 1028.795% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 339.176% |
| NexImmune, Inc. | -29.19 Million USD | 808.011% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | 3777.6% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 1517.465% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 94.893% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 911.839% |
| Scopus BioPharma Inc. | -11.71 Million USD | 1864.304% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 262.665% |
| Ainos, Inc. | -13.2 Million USD | 1665.045% |
| Pluri Inc. | -22.15 Million USD | 1032.783% |
| Prothena Corporation plc | -191.03 Million USD | 208.192% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 249.731% |
| Celularity Inc. | -192.28 Million USD | 207.488% |
| Rallybio Corporation | -78.93 Million USD | 361.853% |
| Cue Biopharma, Inc. | -52.14 Million USD | 496.337% |
| MeiraGTx Holdings plc | -137.06 Million USD | 250.799% |
| Omeros Corporation | -164.53 Million USD | 225.622% |
| Humacyte, Inc. | -100.04 Million USD | 306.589% |
| Immunocore Holdings plc | -59.64 Million USD | 446.504% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 1213.67% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 944.202% |
| Blueprint Medicines Corporation | -486.27 Million USD | 142.504% |
| CalciMedica, Inc. | -21.87 Million USD | 1044.85% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 376.836% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 257.194% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 220.661% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 163.226% |
| Pulmatrix, Inc. | -14.74 Million USD | 1502.212% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 678.224% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 332.582% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 140.111% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 405.97% |
| Cytokinetics, Incorporated | -496.2 Million USD | 141.653% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 700.5% |
| Nutriband Inc. | -4.87 Million USD | 4342.388% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 573.909% |
| Vor Biopharma Inc. | -126.03 Million USD | 263.99% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 95.128% |
| Evogene Ltd. | -26.39 Million USD | 883.169% |
| ProKidney Corp. | -151.52 Million USD | 236.407% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 420.27% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | 2786.941% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 134.03% |
| CorMedix Inc. | -48.95 Million USD | 522.172% |
| BioLineRx Ltd. | -49.69 Million USD | 515.917% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 281.029% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 642.882% |
| Atai Life Sciences N.V. | -125.47 Million USD | 264.728% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 353.17% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 353.886% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 183.01% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 772.368% |
| MediciNova, Inc. | -9.9 Million USD | 2187.681% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 263.552% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 2953.81% |
| GeoVax Labs, Inc. | -26.74 Million USD | 872.862% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 189.156% |
| Biomea Fusion, Inc. | -126.13 Million USD | 263.861% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 159.154% |
| Mereo BioPharma Group plc | -28.41 Million USD | 827.358% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 208.162% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 189.881% |
| Absci Corporation | -115.51 Million USD | 278.926% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 849.215% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 283.123% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 185.35% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 920.313% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 199.371% |
| Allakos Inc. | -196.05 Million USD | 205.422% |
| Imunon, Inc. | -21.03 Million USD | 1082.795% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 286.769% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -92.657% |
| BioAtla, Inc. | -129.68 Million USD | 259.373% |
| NLS Pharmaceutics AG | -11.8 Million USD | 1850.528% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 1404.589% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 163.065% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 594.961% |
| XOMA Corporation | -41.84 Million USD | 593.897% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 296.401% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 270.119% |
| aTyr Pharma, Inc. | -54.91 Million USD | 476.347% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 336.41% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 219.562% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 181.229% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 1062.853% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | 2616.646% |
| Akari Therapeutics, Plc | -16.8 Million USD | 1329.835% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 2337375.798% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 38.773% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 3263.228% |
| UroGen Pharma Ltd. | -65.53 Million USD | 415.378% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 331.508% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 2945.734% |
| Orgenesis Inc. | -53.63 Million USD | 485.349% |
| Entera Bio Ltd. | -8.89 Million USD | 2424.665% |
| GH Research PLC | -41.22 Million USD | 601.397% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 903.975% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 348.86% |
| Xencor, Inc. | -138.63 Million USD | 249.082% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | 4109.752% |
| Replimune Group, Inc. | -234.77 Million USD | 188.037% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 1061.727% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 1581.408% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 3263.228% |
| Portage Biotech Inc. | -18.25 Million USD | 1232.34% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 2953.81% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 296.917% |
| OncoCyte Corporation | -25.13 Million USD | 922.271% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 1928.294% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 1904.005% |
| Purple Biotech Ltd. | 22.27 Million USD | -828.05% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | 2851.411% |
| scPharmaceuticals Inc. | -55.39 Million USD | 473.106% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 1193.71% |
| HilleVax, Inc. | -133.34 Million USD | 255.001% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 1815.379% |
| Tharimmune, Inc. | -9.45 Million USD | 2285.946% |
| Genprex, Inc. | -31.07 Million USD | 765.108% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 209.826% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 758.718% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | 27117.778% |
| Virios Therapeutics, Inc. | -5.44 Million USD | 3894.549% |
| OKYO Pharma Limited | -15.74 Thousand USD | 1312414.56% |
| Savara Inc. | -60 Million USD | 444.436% |
| Curis, Inc. | -48.33 Million USD | 527.638% |
| Daré Bioscience, Inc. | -30.83 Million USD | 770.191% |
| Carmell Therapeutics Corporation | -5.21 Million USD | 4061.566% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | 2940.264% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 858.481% |
| BeiGene, Ltd. | -1.2 Billion USD | 117.114% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 1136.576% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 142.425% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 320.696% |
| Erasca, Inc. | -141.52 Million USD | 246.042% |
| bluebird bio, Inc. | -244.26 Million USD | 184.617% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 4665.655% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -6.298% |
| DBV Technologies S.A. | -76.43 Million USD | 370.418% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 4665.655% |
| Moderna, Inc. | -4.23 Billion USD | 104.876% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 585.076% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | 3349.78% |
| Molecular Templates, Inc. | -10.46 Million USD | 2074.833% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 407.399% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 154.861% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 244.222% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 497.527% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 233.741% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 199.306% |
| MacroGenics, Inc. | -168.24 Million USD | 222.849% |
| RenovoRx, Inc. | -11.39 Million USD | 1913.671% |
| Adicet Bio, Inc. | -152.03 Million USD | 235.944% |
| Prime Medicine, Inc. | -191.29 Million USD | 208.047% |
| Aditxt, Inc. | -26.06 Million USD | 893.042% |
| Adagene Inc. | -23.71 Million USD | 971.362% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 2927.404% |
| Quantum-Si incorporated | -111.17 Million USD | 285.917% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 753.078% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 1517.816% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | -69.395% |
| SciSparc Ltd. | -5.77 Million USD | 3680.218% |
| Vericel Corporation | -6.46 Million USD | 3297.494% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 2487.594% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 993.987% |
| Generation Bio Co. | -138.56 Million USD | 249.164% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 348.929% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 339.054% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 185.726% |
| Invivyd, Inc. | -207.78 Million USD | 199.472% |
| Relay Therapeutics, Inc. | -373 Million USD | 155.412% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 2303.827% |
| Spero Therapeutics, Inc. | 21.48 Million USD | -862.181% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 2109.196% |
| 2seventy bio, Inc. | -216.7 Million USD | 195.378% |
| ADMA Biologics, Inc. | 21.63 Million USD | -855.464% |
| Clene Inc. | -40.54 Million USD | 609.832% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 958.407% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 477.192% |
| GeoVax Labs, Inc. | -26.74 Million USD | 872.862% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 159.043% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 662.686% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | -1185.601% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 299.308% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 707.864% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 221.382% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 130.204% |
| Evaxion Biotech A/S | -22.19 Million USD | 1031.144% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 350.887% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 192.633% |
| Trevena, Inc. | -35.28 Million USD | 685.712% |
| Surrozen, Inc. | -45.78 Million USD | 551.477% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 358.535% |
| Cingulate Inc. | -22.75 Million USD | 1008.143% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | -2658.756% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 562.726% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | 2610.171% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 301.531% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 381.669% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 432.967% |
| Clearmind Medicine Inc. | -8.74 Million USD | 2464.463% |
| Kronos Bio, Inc. | -121.83 Million USD | 269.651% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 371.256% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 7146.95% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 304.991% |
| Statera Biopharma, Inc. | -98.34 Million USD | 310.167% |
| ImmunityBio, Inc. | -362.25 Million USD | 157.056% |
| Korro Bio, Inc. | -84.53 Million USD | 344.5% |
| Kineta, Inc. | -15.72 Million USD | 1414.546% |
| BioVie Inc. | -32.17 Million USD | 742.289% |
| Codexis, Inc. | -68.06 Million USD | 403.642% |
| Celularity Inc. | -192.28 Million USD | 207.488% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 192.848% |
| Celcuity Inc. | -66.23 Million USD | 412.072% |
| Virax Biolabs Group Limited | -6.49 Million USD | 3281.511% |
| Cibus, Inc. | -318.88 Million USD | 164.816% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 580.665% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 710.702% |
| IN8bio, Inc. | -30.33 Million USD | 781.3% |
| Kodiak Sciences Inc. | -277.32 Million USD | 174.53% |
| Annexon, Inc. | -143.72 Million USD | 243.809% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 266.964% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 419.72% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 981.616% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 158.43% |
| Eyenovia, Inc. | -25.4 Million USD | 913.518% |
| Puma Biotechnology, Inc. | 32.64 Million USD | -533.229% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 3816.037% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 361.188% |
| Arcellx, Inc. | -89.88 Million USD | 329.958% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 555.135% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 250.638% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 764.393% |
| Moolec Science SA | -6.65 Million USD | 3206.283% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 438.065% |
| Geron Corporation | -193.94 Million USD | 206.57% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 577.854% |
| Royalty Pharma plc | 1.49 Billion USD | 86.148% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 225.904% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 2315.791% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 1044.002% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 220.899% |
| Humacyte, Inc. | -100.04 Million USD | 306.589% |
| Structure Therapeutics Inc. | -102.77 Million USD | 301.105% |
| 89bio, Inc. | -151.2 Million USD | 236.693% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 357.932% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 1521.499% |
| Genelux Corporation | -24.16 Million USD | 955.311% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 709.28% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 220.341% |
| Notable Labs, Ltd. | -14.65 Million USD | 1510.152% |
| Liquidia Corporation | -73.38 Million USD | 381.65% |
| Mustang Bio, Inc. | -50.72 Million USD | 507.456% |
| Immunovant, Inc. | -282.7 Million USD | 173.109% |
| Quantum-Si incorporated | -111.17 Million USD | 285.917% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 364.633% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 1071.863% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 302.609% |
| Acasti Pharma Inc. | -11.31 Million USD | 1927.139% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 1001.728% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 1393.456% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 196.558% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | 5733.196% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 1401.058% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 808.873% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 599.435% |
| PepGen Inc. | -84.76 Million USD | 343.831% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 797.533% |
| United Therapeutics Corporation | 1.18 Billion USD | 82.557% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 1002.677% |
| Solid Biosciences Inc. | -104.31 Million USD | 298.136% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 729.984% |
| Immuneering Corporation | -58.41 Million USD | 453.836% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 4160.44% |
| Silo Pharma, Inc. | -3.85 Million USD | 5460.681% |
| Belite Bio, Inc | -31.66 Million USD | 752.665% |
| XOMA Corporation | -41.84 Million USD | 593.897% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 406.111% |
| Bionomics Limited | -17.89 Billion USD | 101.155% |
| Apogee Therapeutics, Inc. | -93 Million USD | 322.236% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -479.277% |
| uniQure N.V. | -282.87 Million USD | 173.067% |
| Cassava Sciences, Inc. | -105.95 Million USD | 295.066% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 2927.404% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 259.598% |
| Forte Biosciences, Inc. | -32.48 Million USD | 736.231% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 2587.569% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 803.133% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 3816.037% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 1554.511% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 2425.188% |
| Altimmune, Inc. | -95.92 Million USD | 315.457% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 381.228% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -479.277% |
| Compugen Ltd. | -12.99 Million USD | 1690.871% |
| Peak Bio, Inc. | -1356.23 USD | 15239845.471% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 516.672% |
| Benitec Biopharma Inc. | -22.49 Million USD | 1019.013% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 185.301% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 794.836% |
| Zura Bio Limited | -62.63 Million USD | 429.969% |
| PolyPid Ltd. | -22.86 Million USD | 1003.861% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 1369.882% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 794.836% |
| Instil Bio, Inc. | -159.16 Million USD | 229.853% |
| argenx SE | -425.04 Million USD | 148.626% |
| Immunome, Inc. | -109.53 Million USD | 288.703% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 510.393% |
| Verona Pharma plc | -67.83 Million USD | 404.708% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 893.116% |
| Shattuck Labs, Inc. | -91.95 Million USD | 324.764% |
| CervoMed Inc. | -7.81 Million USD | 2745.447% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 382.706% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 1651.58% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 529.041% |
| Moolec Science SA | -6.65 Million USD | 3206.283% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 1356.569% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 252.844% |
| AnaptysBio, Inc. | -164.41 Million USD | 225.713% |
| Design Therapeutics, Inc. | -78.19 Million USD | 364.338% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 337.458% |
| NeurAxis, Inc. | -6.66 Million USD | 3201.3% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 610.348% |
| Lumos Pharma, Inc. | -36.61 Million USD | 664.5% |
| Achilles Therapeutics plc | -75.25 Million USD | 374.648% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 893.116% |
| 180 Life Sciences Corp. | -13.47 Million USD | 1633.563% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | -3908.408% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 7146.95% |
| Nutriband Inc. | -4.87 Million USD | 4342.388% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 286.573% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 472.75% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 506.574% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 412.692% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 481.881% |
| Palisade Bio, Inc. | -13.07 Million USD | 1681.377% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 555.165% |
| Beam Therapeutics Inc. | -176.48 Million USD | 217.113% |
| Neurogene Inc. | -55.58 Million USD | 471.851% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 289.353% |
| AEON Biopharma, Inc. | -48.42 Million USD | 526.781% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 313.717% |
| Sesen Bio, Inc. | -25.9 Million USD | 897.738% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 347.442% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 1742.073% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 144.877% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 385.324% |
| Athira Pharma, Inc. | -125.46 Million USD | 264.735% |
| Vaccinex, Inc. | -22.88 Million USD | 1003.151% |
| HCW Biologics Inc. | -25.71 Million USD | 903.689% |
| XOMA Corporation | -41.84 Million USD | 593.897% |
| Nektar Therapeutics | -137.42 Million USD | 250.399% |
| Arvinas, Inc. | -401.5 Million USD | 151.478% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 2337375.798% |
| Merus N.V. | -156.54 Million USD | 232.028% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 306.148% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 697.013% |
| Rezolute, Inc. | -70.42 Million USD | 393.492% |
| Clene Inc. | -40.54 Million USD | 609.832% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 1361.937% |
| BeyondSpring Inc. | -23.11 Million USD | 994.203% |
| Synlogic, Inc. | -55.16 Million USD | 474.696% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 1252.803% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 2009.516% |
| Peak Bio, Inc. | -1356.23 USD | 15239845.471% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 610.298% |
| Krystal Biotech, Inc. | -109.72 Million USD | 288.364% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 259.554% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 160.256% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | 4454.995% |
| MannKind Corporation | 8.67 Million USD | -2281.724% |
| Ikena Oncology, Inc. | -75.41 Million USD | 374.058% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 2242.49% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 407.431% |
| Gossamer Bio, Inc. | -183.75 Million USD | 212.477% |
| CohBar, Inc. | -12.38 Million USD | 1768.397% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 507.472% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 849.215% |
| Legend Biotech Corporation | -439.48 Million USD | 147.029% |
| Mural Oncology plc | -194.63 Million USD | 206.19% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 407.83% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 1380.164% |
| Disc Medicine, Inc. | -91.12 Million USD | 326.816% |
| Champions Oncology, Inc. | -7.35 Million USD | 2909.761% |
| REGENXBIO Inc. | -268.12 Million USD | 177.085% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 2028.367% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 470.697% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 630.499% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 280.738% |
| Vaxart, Inc. | -83.34 Million USD | 347.983% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 2525.89% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 582.978% |
| Cellectis S.A. | -106.62 Million USD | 293.842% |
| Longeveron Inc. | -21.02 Million USD | 1082.862% |
| Repare Therapeutics Inc. | -116.22 Million USD | 277.834% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 177.172% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 373.232% |
| Revolution Medicines, Inc. | -487.18 Million USD | 142.425% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | 3207.126% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 570.233% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 377.096% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 396.813% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 1977.087% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 95.202% |
| Denali Therapeutics Inc. | -196.69 Million USD | 205.077% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 2487.594% |
| Veru Inc. | -93.78 Million USD | 320.389% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 985.962% |
| Cingulate Inc. | -22.75 Million USD | 1008.143% |
| Passage Bio, Inc. | -108.38 Million USD | 290.689% |
| Context Therapeutics Inc. | -25.07 Million USD | 924.35% |
| Exicure, Inc. | -14.99 Million USD | 1478.274% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 200.302% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 609.104% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 2227.069% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 212.112% |
| Nuvalent, Inc. | -149.49 Million USD | 238.259% |
| ABVC BioPharma, Inc. | -8.21 Million USD | 2615.497% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 332.936% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 1094.926% |
| OmniAb, Inc. | -69.41 Million USD | 397.737% |
| Anew Medical, Inc. | -1.3 Million USD | 15988.657% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 1718.401% |
| Lipocine Inc. | -17.93 Million USD | 1252.677% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 401.674% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 371.412% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 642.835% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 622.898% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 1023.365% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 135.645% |
| Ocugen, Inc. | -65.53 Million USD | 415.402% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 320.193% |
| Q32 Bio Inc. | -92.1 Million USD | 324.41% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 1064.065% |
| Alumis Inc. Common Stock | -158.17 Million USD | 230.67% |
| Equillium, Inc. | -14.52 Million USD | 1523.261% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 431.196% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 2715.17% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 1195.599% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 540.216% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 290.554% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 1826.698% |
| Dominari Holdings Inc. | -21.79 Million USD | 1048.275% |
| Edesa Biotech, Inc. | -9.22 Million USD | 2341.043% |
| vTv Therapeutics Inc. | -25.5 Million USD | 910.47% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 152.795% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | -7.632% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 256.252% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 638.371% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 236.787% |
| Nkarta, Inc. | -131.65 Million USD | 256.997% |
| BioCardia, Inc. | -11.64 Million USD | 1875.043% |
| Iterum Therapeutics plc | -47.46 Million USD | 535.422% |